SERPINC1 and venous thromboembolism: Among patients diagnosed with venous thromboembolism (VTE), the prevalence is estimated to reach approximately 1%.6Most of AT-deficient patients carry heterozygous SERPINC1 variants.7Studies conducted in an experimental mouse model have demonstrated that a homozygous null variant in the SERPINC1 gene leads to embryonic lethality, attributed to bleeding complications and severe thrombosis.8Over 300 genetic variants responsible for AT deficiency have been discovered for the SERPINC1 gene.6Variants of SERPINC1 gene lead to abnormal levels of AT in the peripheral blood.9